Insmed (INSM) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Insmed (INSM) over the past year, gaining 57.2% versus a loss of 37.3%. Over five years, INSM leads with a +284.1% price change compared with +47.9% for RPRX. Royalty Pharma is the larger company by market cap ($32.48 billion vs $21.94 billion), about 1.5 times the size, while Insmed is growing revenue faster (+66.7% vs +5.1%).
On valuation, Royalty Pharma trades at a lower forward P/E (9.8x vs 127.6x for Insmed). Royalty Pharma pays a dividend yielding 1.62%, while Insmed does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | RPRX |
|---|---|---|
| Share price | $100.48 | $56.21 |
| Market cap | $21.94B | $32.48B |
| 1-day change | -1.24% | -0.97% |
| YTD return | -41.54% | +46.89% |
| 1-year return | -37.32% | +57.23% |
| 5-year return | +284.07% | +47.85% |
| P/E ratio (TTM) | — | 29.90 |
| Forward P/E | 127.61 | 9.80 |
| EPS (TTM) | $-4.10 | $1.88 |
| Dividend yield | 0.00% | 1.62% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $606.42M | $2.38B |
| Revenue growth (YoY) | +66.73% | +5.06% |
| Net income (latest FY) | $-1.28B | $770.95M |
| Gross margin | 79.73% | — |
| Operating margin | -205.59% | 65.58% |
| Net margin | -210.54% | 32.42% |
| 52-week high | $212.75 | $64.38 |
| 52-week low | $90.39 | $35.23 |
| Distance from 52-week high | -52.77% | -12.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.80% | +16.31% |
| Average volume | 2.57M | 2.93M |
| Shares outstanding | 218.38M | 445.28M |
| Employees | 1,664 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed INSM by 94.6 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.62% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +5.06%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
INSM vs RPRX FAQ
Which is bigger, Insmed or Royalty Pharma?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.48B compared with $21.94B for Insmed (INSM).
Which stock has performed better over the past year, INSM or RPRX?
RPRX returned +57.23% over the past 12 months, compared with -37.32% for INSM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Insmed or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.62%, while Insmed does not currently pay a regular dividend.
Are Insmed and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.